Evolution of viral quasispecies during SARS-CoV-2 infection
Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: Studies are needed to better understand the genomic evolution of the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to describe genomic diversity of SARS-CoV-2 by next-generation sequencing (NGS) in a patient with longitudinal follow-up for SARS-CoV-2 infection.
METHODS: Sequential samples collected between January 29th and February 4th, 2020, from a patient infected by SARS-CoV-2 were used to perform amplification of two genome fragments-including genes encoding spike, envelope, membrane and nucleocapsid proteins-and NGS was carried out with Illumina® technology. Phylogenetic analysis was performed with PhyML and viral variant identification with VarScan.
RESULTS: Majority consensus sequences were identical in most of the samples (5/7) and differed in one synonymous mutation from the Wuhan reference sequence. We identified 233 variants; each sample harboured in median 38 different minority variants, and only four were shared by different samples. The frequency of mutation was similar between genes and correlated with the length of the gene (r = 0.93, p = 0.0002). Most of mutations were substitution variations (n = 217, 93.1%) and about 50% had moderate or high impact on gene expression. Viral variants also differed between lower and upper respiratory tract samples collected on the same day, suggesting independent sites of replication of SARS-CoV-2.
CONCLUSIONS: We report for the first time minority viral populations representing up to 1% during the course of SARS-CoV-2 infection. Quasispecies were different from one day to the next, as well as between anatomical sites, suggesting that in vivo this new coronavirus appears as a complex and dynamic distributions of variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 26(2020), 11 vom: 15. Nov., Seite 1560.e1-1560.e4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jary, Aude [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Infection follow-up |
|---|
| Anmerkungen: |
Date Completed 20.11.2020 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2020.07.032 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312932413 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312932413 | ||
| 003 | DE-627 | ||
| 005 | 20231225145500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2020.07.032 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM312932413 | ||
| 035 | |a (NLM)32717416 | ||
| 035 | |a (PII)S1198-743X(20)30440-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jary, Aude |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolution of viral quasispecies during SARS-CoV-2 infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2020 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: Studies are needed to better understand the genomic evolution of the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to describe genomic diversity of SARS-CoV-2 by next-generation sequencing (NGS) in a patient with longitudinal follow-up for SARS-CoV-2 infection | ||
| 520 | |a METHODS: Sequential samples collected between January 29th and February 4th, 2020, from a patient infected by SARS-CoV-2 were used to perform amplification of two genome fragments-including genes encoding spike, envelope, membrane and nucleocapsid proteins-and NGS was carried out with Illumina® technology. Phylogenetic analysis was performed with PhyML and viral variant identification with VarScan | ||
| 520 | |a RESULTS: Majority consensus sequences were identical in most of the samples (5/7) and differed in one synonymous mutation from the Wuhan reference sequence. We identified 233 variants; each sample harboured in median 38 different minority variants, and only four were shared by different samples. The frequency of mutation was similar between genes and correlated with the length of the gene (r = 0.93, p = 0.0002). Most of mutations were substitution variations (n = 217, 93.1%) and about 50% had moderate or high impact on gene expression. Viral variants also differed between lower and upper respiratory tract samples collected on the same day, suggesting independent sites of replication of SARS-CoV-2 | ||
| 520 | |a CONCLUSIONS: We report for the first time minority viral populations representing up to 1% during the course of SARS-CoV-2 infection. Quasispecies were different from one day to the next, as well as between anatomical sites, suggesting that in vivo this new coronavirus appears as a complex and dynamic distributions of variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Infection follow-up | |
| 650 | 4 | |a Minority variants | |
| 650 | 4 | |a NGS | |
| 650 | 4 | |a Quasispecies | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 700 | 1 | |a Leducq, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Malet, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Marot, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Klement-Frutos, Elise |e verfasserin |4 aut | |
| 700 | 1 | |a Teyssou, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Soulié, Cathia |e verfasserin |4 aut | |
| 700 | 1 | |a Abdi, Basma |e verfasserin |4 aut | |
| 700 | 1 | |a Wirden, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Pourcher, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Caumes, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Calvez, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Burrel, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Marcelin, Anne-Geneviève |e verfasserin |4 aut | |
| 700 | 1 | |a Boutolleau, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 26(2020), 11 vom: 15. Nov., Seite 1560.e1-1560.e4 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:11 |g day:15 |g month:11 |g pages:1560.e1-1560.e4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2020.07.032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2020 |e 11 |b 15 |c 11 |h 1560.e1-1560.e4 | ||